Syngenta

Last updated January 31, 2026

Innovation Areas

1,941

Inventors

Collaborations

Fused imidazopyrazine and benzimidazole scaffolds: SyngentaRecent Research Landscape

Off-target binding and poor metabolic stability in kinase inhibition lead to high drug failure rates. These specific heterocyclic scaffolds are engineered to optimize binding affinity and pharmacokinetic profiles.

What technical problems is Syngenta addressing in Fused imidazopyrazine and benzimidazole scaffolds?

Pathogenic microbial infestation

(13)evidences

Uncontrolled growth of harmful microorganisms leads to crop loss and material degradation. Inhibiting these biological agents prevents systemic infection and economic damage.

Dysregulated kinase signaling activity

(11)evidences

Dysregulated phosphorylation pathways lead to uncontrolled cellular proliferation and disease progression. Inhibiting these specific enzymatic malfunctions restores normal cellular homeostasis.

Crop fungal pathogen resistance

(1)evidences

Uncontrolled growth of harmful microorganisms leads to infection and material decay. Inhibiting these biological agents prevents disease transmission and structural degradation.